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Sulfatide derived from the myelin stimulates a distinct population of CD1d-restricted 
natural killer T (NKT) cells. Cis-tetracosenoyl sulfatide is one of the immunodominant 
species in myelin as identified by proliferation, cytokine secretion, and CD1d tetramer 
staining. The crystal structure of mouse CD1d in complex with cis-tetracosenoyl sulfatide at 
1.9 Å resolution reveals that the longer cis-tetracosenoyl fatty acid chain fully occupies the 
A
 
  
 
pocket of the CD1d binding groove, whereas the sphingosine chain fills up the F
 
  
 
pocket. 
A precise hydrogen bond network in the center of the binding groove orients and positions 
the ceramide backbone for insertion of the lipid tails in their respective pockets. The 3
 
 
 
-
sulfated galactose headgroup is highly exposed for presentation to the T cell receptor and 
projects up and away from the binding pocket due to its 
 
  
 
linkage, compared with the more 
intimate binding of the 
 
 
 
-glactosyl ceramide headgroup to CD1d. These structure and 
binding data on sulfatide presentation by CD1d have important implications for the design 
of therapeutics that target T cells reactive for myelin glycolipids in autoimmune diseases of 
the central nervous system.
 
Innate pathways of immunity are important
not only in providing a rapid response against
infectious agents, but also in the effective induc-
tion and/or modulation of adaptive responses.
Natural killer T (NKT) cells that share the cell-
surface receptors of NK cells and, in addition,
express an antigen receptor (TCR) are generally
stimulated by lipid antigens and rapidly secrete
large amounts of IFN-
 
  
 
and IL-4 after activation
(1). NKT cells influence the outcome of the
immune response against tumors and infectious
organisms, as well as the course of several au-
toimmune diseases (2, 3).
NKT cells recognize lipid antigens when
bound by nonpolymorphic, MHC class I–like
CD1 molecules (4). APCs, such as dendritic
cells, macrophages, and subsets of B cells, express
CD1 molecules. The CD1 family consists of
five distinct genes (CD1a–e) that can be cate-
gorized into two groups. In humans, group 1
consists of CD1a, CD1b, CD1c, and CD1e,
whereas CD1d is the only member of group
two and is also expressed in mice.
The first crystal structure of mouse CD1d
revealed a deep hydrophobic ligand binding
groove, which seems to be well-suited for the
binding of long chain hydrophobic compounds,
such as lipids, where electron density for two
long aliphatic chains was observed, but not
fully interpreted, in the binding groove (5).
Recently, this bound self-ligand was identified
as phosphatidyl choline (PC), and the CD1d
crystal structure confirmed that the two lipid
tails are inserted into the A
 
  
 
and F
 
  
 
pockets,
with the headgroup extending out of the
groove for T cell recognition (6).
Other structural determinations of a variety
of CD1–ligand complex structures, such as
CD1a–sulfatide (7), CD1a–lipopeptide (8),
CD1b–phosphatidyl inositol, and CD1b–GM2
(9), CD1b–glucose monomycolate (10), mouse
CD1d–
 
 
 
-galactosyl ceramide (
 
 
 
-GalCer; short-
chain, C
 
8
 
; reference 11), and human CD1d–
 
 
 
-
GalCer (long-chain, C
 
26
 
; reference 12), have
provided fascinating insights into the general
mode of ligand binding and elucidated the basis
for CD1 isotype-specific variation. Each lipid
ligand inserts its aliphatic moieties, either two
alkyl chains for glycolipids or one alkyl chain
for lipopeptides, into the deeply buried hydro-
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phobic cavities of CD1, thereby positioning the diverse T
cell epitopes, carbohydrate moieties for glycolipids and pep-
tidic moieties for lipopeptides, above the hydrophobic bind-
ing groove on the CD1 surface for inspection by TCRs spe-
cific for either the ligand and/or the CD1 isoform (13).
Because different lipids are either present in or traffic to
distinct endocytic compartments, it has been suggested that
the different CD1 isotypes have evolved to target these vari-
ous intracellular locations. CD1b and CD1d are localized
mainly in the late endosomes or lysosomes where microbial
lipids accumulate after infection, whereas CD1a recycles
back to the cell surface via passage through early or recycling
endosomes (14, 15). Recently, a family of endosomal lipid
transfer proteins, the saposins, has been shown to be neces-
sary for the presentation of certain lipids by CD1. It has been
proposed that these saposins have the ability to extract and
bind monomeric lipids from the membrane, which could
then be transferred through a yet unknown mechanism to
CD1 in the endosomal compartments (16–18).
Characterization of lipid-reactive NKT cells and their
function is important for understanding the role of this NKT
cell subset in the spectrum of immune responses. NKT cells
have regulatory effects in both experimental models and in
human autoimmune diseases, such as diabetes and multiple
sclerosis (2, 3). These cells are autoreactive and express a
memory/activation phenotype. NKT cells are heteroge-
neous, but most of their phenotypic and functional charac-
teristics have been derived from studies of the major mouse
NKT cell population that expresses TCRs with an invariant
V
 
 
 
14
 
  
 
 
 
-chain (V
 
 
 
24
 
  
 
in human). A nonmammalian gly-
colipid, 
 
 
 
-GalCer, has been invaluable as a highly potent,
stimulatory ligand for these NKT cells in the context of
CD1d. 
 
 
 
-GalCer, unlike most mammalian glycolipids, has
its carbohydrate moiety attached via an 
 
 
 
 rather than a 
 
 
 
linkage. Thus, very little is known about the phenotype or
physiological relevance of self-glycolipid–reactive NKT cells
compared with the 
 
 
 
-GalCer–reactive invariant NKT cells.
Recently, self-lipids have been identified as ligands for
both invariant (i) and variant CD1d-restricted NKT cells
(19–21). Although iNKT cells recognize isoglobotrihexosyl
ceramide (iGB3), a distinct CD1d-restricted population rec-
ognizes sulfatide when presented by CD1d (19, 20). Staining
of cells with sulfatide–CD1d–tetrameric complexes ex vivo
demonstrated that sulfatide-reactive NKT cells are present in
the liver, thymus, and spleen. Interestingly, during the nor-
mal course of experimental autoimmune encephalomyelitis
(EAE), a prototype model for T cell–mediated autoimmune
disease that is characterized by inflammation and demyelina-
tion in the central nervous system (CNS), NKT cells reac-
tive against sulfatide–CD1d tetramers, but not 
 
 
 
-GalCer–
CD1d tetramers, are increased severalfold within the CNS
(19). Furthermore, the treatment of mice with 20 mg sul-
fatide prevents antigen (MOG35-55 peptide)-induced EAE
in CD1d
 
 
 
/
 
  
 
mice, but not in CD1d
 
 
 
/
 
  
 
C57BL/6 mice (19).
Thus, a sulfatide-reactive subset of NKT cells can be tar-
geted for manipulation of autoimmune responses in experi-
mental autoimmunity.
In an attempt to characterize self-glycolipid recognition
by NKT cells and, more precisely, to elucidate the structural
differences in ligand binding and NKT cell stimulation be-
tween 
 
 
 
-anomeric (
 
 
 
-GalCer) versus 
 
 
 
-anomeric (sulfatide)
glycolipids by mouse CD1d, we crystallized CD1d in com-
plex with a synthetic sulfatide self-antigen and determined its
three-dimensional structure at 1.9 Å resolution.
 
RESULTS
Sulfatide recognition by CD1-restricted T cells
 
One of the most abundant galactolipids in the axon-insulat-
ing myelin sheet of the CNS is 3
 
 
 
 sulfogalactosyl ceramide
(sulfatide), in which the 3
 
  
 
OH of galactose is sulfated and
the sugar is attached to the ceramide via a 
 
 
 
-glycosidic link-
Figure 1. CD1d loading and T cell recognition of sulfatide. 
(A) Dominant response to cis-tetracosenoyl sulfatide as examined by in 
vitro proliferation to a titrated dose of cis-tetracosenoyl (C24:1) sulfatide 
( ), tetracosanoyl (C24:0) sulfatide ( ), lyso-sulfatide (no fatty acid;  ), 
and palmitoyl (C16:0) sulfatide ( ) in splenocytes from C57BL/6 mice. One 
of three representative experiments is shown. (B) Loading of cis-tetracosenoyl 
sulfatide onto mouse CD1d molecules. 9  g of purified mouse CD1d protein 
was incubated at 37 C for 6 h with 4  g of purified sulfatide (sulf) from 
bovine brain or synthetic cis-tetracosenoyl sulfatide (cis) and subjected to 
IEF gel electrophoresis. One of two representative experiments is shown. 
(C) Staining of mononuclear cells from liver with cis-tetracosenoyl sulfatide 
CD1d/tetramer. Flow cytometric analysis of liver mononuclear cells from 
CD1d /  (C57BL/6, panels 1 and 2, or SJL/J, panel 3) and C57BL/6.CD1d /  
mice (panel 4) after staining with either cis-tetracosenoyl sulfatide loaded 
or unloaded CD1d tetramers, which were labeled with phycoerythrin (PE) 
and anti–TCR- –FITC. In each panel, the numbers indicate the percent of 
positive cells. One of three representative experiments is shown. (D) Prolif-
eration and cytokine secretion response of splenocytes from naive C57BL/6 
( ) or C57BL/6.CD1d /  ( ) mice to an in vitro stimulation with a titrated 
dose of cis-tetracosenoyl sulfatide. One of five representative experiments 
is shown. 
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age. We have shown that sulfatide is recognized by a subset
of CD1d-restricted T cells that are distinct from the invariant
V
 
 
 
14
 
 
 
 T cells that respond to the potent glycolipid, 
 
 
 
-Gal-
Cer, as well as to a sphingolipid self-antigen, iGB3, and the
microbial glycuronosyl ceramides (4, 20). Sulfatides derived
from the brain are comprised of several molecular species
that differ in length of their acyl chain and in the extent of
the unsaturation and hydroxylation of the N-amide–linked
fatty acid of the ceramide backbone. Thus, natural sulfatide
is a 2:1 mixture of saturated and unsaturated fatty acyl chains
with tetracosanoyl (C
 
24
 
) constituting the predominant chain
length (22).
To analyze the fine specificity of sulfatide-reactive T
cells, we have used synthetic homologues or analogs of sul-
fatide comprised of different fatty acid chain lengths (C
 
16
 
–
C
 
24
 
) to characterize the immunodominant sulfatide species.
In vitro proliferation or cytokine secretion assays were used
to determined the most active species as cis-tetracosenoyl
(C
 
24:1
 
, mono-unsaturated fatty acid) sulfatide (Fig. 1 A).
Other sulfatides, including tetracosanoyl- (C
 
24
 
, saturated
fatty acid), palmitoyl- (C
 
16
 
, saturated fatty acid), and lyso-
sulfatides (lacking the fatty acid chain) did not induce a sig-
nificant immune response (Fig. 1 A). Furthermore, adjuvant-
free administration of cis-tetracosenoyl sulfatide in three
different mouse strains resulted in significant amelioration of
a chronic and relapsing form of EAE (unpublished data).
Sulfatides, either naturally derived from bovine brain or as
synthetic cis-tetracosenoyl species, can be efficiently loaded
onto purified mCD1d, as judged by isoelectric focusing gel
electrophoresis (Fig. 1 B). The negative charge on the sul-
fatide promotes a shift in the migration of exogenously
loaded mCD1d compared with endogenous CD1d, which is
likely loaded with a neutral self-antigen, such as PC (6).
Next, we determined whether synthetic cis-tetracosenoyl
sulfatide is able to form mCD1d-tetramers that can stain NKT
cells, similar to the recent experiments with tetramers that
were loaded with natural sulfatides from bovine brain (19). In
two different CD1d
 
 
 
/
 
 
 
 mouse strains, around 1–2% of T cells
can be stained with cis-tetracosenoyl/mCD1d-tetramers,
whereas no staining was observed in CD1d
 
 
 
/
 
 
 
 mice or when
unloaded tetramers were used to stain NKT cells in a CD1d
 
 
 
/
 
 
 
mouse (Fig. 1 C). To examine the nature of immune response
to cis-tetracosenoyl sulfatide and its dependence on the CD1d
antigen presentation pathway, spleen cells from naive wild-
type mice, as well as CD1d
 
 
 
/
 
 
 
 mice, were cultured with dif-
ferent concentrations of the synthetic glycolipid and assayed
for proliferation as well as IFN-
 
 
 
 and IL-4 secretion (Fig. 1
D). Splenocytes from wild-type mice, but not from CD1d
 
 
 
/
 
 
 
mice, proliferated and produced IFN-
 
 
 
 in response to cis-tet-
racosenoyl sulfatide. No significant secretion of IL-4 was ob-
served under these experimental conditions.
The sulfatide negative charge arises from the 3
 
  
 
sulfate
group. Because mono-GM1 that contains sialic acid, which
is also negatively charged, does not induce proliferative/cy-
tokine responses, and because GM1–CD1d-tetramers do not
stain NKT cells (unpublished data), it seems unlikely that the
negative charge alone is responsible for specific recognition
by NKT cells. In addition, the 3
 
  
 
sulfate group is required
for the activation of sulfatide-specific NKT cells because
 
 
 
-GalCer, which is identical to the sulfatide but lacks the 3
 
 
 
sulfate group, does not stimulate this NKT cell pool. As 3
 
 
 
-
sulfated 
 
 
 
-GalCer is also not able to activate sulfatide-spe-
cific NKT cells (unpublished data), it is suggested that these
sulfatide-reactive NKT cells are specific for the configura-
tion of the sulfated galactose moiety (
 
 
 
 form active, 
 
 
 
 form
inactive) at the CD1d surface.
 
Table I.
 
Data collection and refinement statistics for 
the CD1d–sulfatide complex
 
Data collection
 
Resolution range (Å)
 
a
 
50.0–1.9 (1.97–1.9)
Completeness (%)
 
a
 
98.7 (99.7)
Number of unique reflections 67,171
Redundancy 2.4
R
 
sym
a,b
 
 (%) 8.9 (58.0)
I/
 
 
 
a
 
15.9 (2.4)
 
Refinement statistics
 
Number of reflections (f
 
 
 
0) 65,745
Maximum resolution (Å) 1.9
R
 
cryst
c 
 
(%) 18.6 (26.3)
R
 
free
d 
 
(%) 24.8 (33.7)
 
Number of atoms
 
6,918
Protein 5,948
Glycolipid ligand 122
N-linked carbohydrate 99
Water 749
 
Ramachandran statistics (%)
 
Favored 98.2
Allowed 1.8
 
Root-mean-square deviation from 
ideal geometry
 
Bond length (Å) 0.016
Bond angles (
 
 
 
) 1.75
Average B-values (Å
 
2
 
)
 
e
 
Protein 24.5
Sulfatide (total/ceramide/headgroup/) 42.7/36.5/61.6
Water molecules 34.5
Carbohydrates 37.8
 
a
 
Number in parentheses refer to the highest resolution shell.
 
b
 
R
 
sym 
 
  
 
(
 
 
 
h
 
 
 
i
 
 | I
 
i
 
(h)-
 
 
 
I(h)
 
 
 
I | (
 
 h IIi(h)) 100, where  I(h)  is the average inten-
sity of i symmetry–related observations for reflections with Bragg index h.
cRcryst   ( hkl | Fo-Fc | / hkl | Fo | ) 100, where Fo and Fc are the observed and calcu-
lated structure factors, respectively, for all data.
dRfree was calculated as for Rcryst, but on 3% of data excluded from refinement.
eB-values were calculated with the CCP4 program TLSANL (reference 53).STRUCTURE OF THE MOUSE CD1D–SULFATIDE COMPLEX | Zajonc et al. 1520
Structure determination of the CD1d–sulfatide complex
Soluble and fully glycosylated, heterodimeric mouse CD1d-
 2M protein (residues 1–279 heavy chain and 1–99  2M)
was secreted by Spodoptera frugiperda (SF9) cells upon infec-
tion with recombinant baculovirus and purified to homoge-
neity by affinity and size-exclusion chromatography, as de-
scribed below in Materials and methods. After partial
deglycosylation of the protein using Endoglycosidase H
(Endo H), synthetic cis-tetracosenoyl sulfatide was loaded by
incubating CD1d with a 10-fold molar excess of sulfatide
without any detergents. The CD1d–sulfatide complex was
further purified by size-exclusion chromatography. More
than 95% of the CD1d protein appeared to be loaded with
sulfatide, as judged by native IEF gel electrophoresis (unpub-
lished data). Using the sitting drop vapor diffusion method,
we crystallized the CD1d–sulfatide complex and determined
its three-dimensional structure by molecular replacement us-
ing the protein coordinates of the CD1d short-chain  -Gal-
Cer complex (PDB code 1Z5L) as the search model (Table I
and Fig. 2; reference 11). The crystal structure was refined to
a final Rcryst and Rfree of 18.6 and 24.8%, respectively. The
asymmetric unit of the crystal contains two CD1d–sulfatide
complexes (A and B), which are very similar (root-mean-
square deviation of 0.55 Å for all C  atoms). Thus, we de-
scribe here only the crystal structure for complex A, except
where stated otherwise.
Structural features of the mouse CD1d–sulfatide complex
The overall architecture of mouse CD1d has been described
(5, 6, 11). The binding groove of CD1d is formed by two
anti-parallel  -helices that sit atop a six-stranded,  -sheet
platform and is lined mainly by hydrophobic residues (Fig. 2
A). The two major pockets, A  and F , are located deep in-
side the CD1 protein and each accommodate one alkyl chain
of the sulfatide ligand. The sulfated galactose headgroup is
then positioned above the binding groove at the interface
between both pockets (Fig. 2 B). As the A  pocket is larger
in volume than the F  pocket, the synthetic sulfatide (Fig. 2
C, left) binds such that the longer cis-tetracosenoyl fatty acid
(C24:1) occupies the A  pocket, whereas the shorter sphingo-
sine backbone (C18) is inserted into the F  pocket. As the
sulfatide alkyl chains then fully occupy both binding pockets,
the previously reported spacer lipid (11) is not observed in
the CD1d binding groove. Although the electron density is
relatively weak at the junction where the cis-tetracosenoyl
fatty acid starts to encircle the central pole of the A  pocket,
the fatty acid appears to go around the A  pole in a counter-
clockwise direction when looking down into the binding
groove (Fig. 3, A and B). This conformation places the cis-
unsaturation in the middle of the fatty acid curvature, which
could facilitate the encircling of the pole. Several water mol-
ecules are located in the vicinity of the polar groups of the
sulfatide, mainly proximal to the galactosylsulfate headgroup,
which suggests that these waters play a role in the CD1–
ligand interaction (Figs. 3 and 4). In contrast, no water mol-
ecules could be observed at similar locations in the CD1d
short-chain  -GalCer (PBS-25) structure (11), likely due to
the closer binding of the  -linked galactose to the  2-helix
of CD1d.
As in the CD1d–PBS-25 structure, the electron density
is best defined for the polar region of the sphingosine back-
bone and the connection with the fatty acid (Fig. 3), as hy-
drogen bonds with CD1d residues stabilize and provide
specificity for this region of the ligand (Fig. 4). Seven hydro-
gen bonds are formed directly between CD1 and the sul-
fatide, whereas two additional hydrogen bonds are mediated
by water molecules—one between the sulfate group and the
backbone nitrogen of Gln154 and the other between the
keto group of the fatty acid and the backbone oxygen of
Met69. The same CD1 residues are involved in hydrogen
bond formation with the short-chain  -GalCer ligand PBS-
25. Although several residues of the  1-helix (Asp80, Arg79,
and Met69) provide specific contacts to the ceramide back-
Figure 2. Overview of the CD1d–sulfatide structure. (A) Schematic 
representation (front view) of the CD1d ( 1– 3 domains)- 2M heterodimer 
(gray) with  -strands and  -helices highlighted and with bound cis-
tetracosenoyl sulfatide ligand in stick representation (yellow). N-linked 
carbohydrates are depicted as gray stick models. Atom colors for all structural 
representations are as follows: yellow/gray, carbon; red, oxygen; blue, 
nitrogen; orange, sulfate. (B) Top view looking into the CD1d-binding 
groove. The sulfatide fatty acid is bound in the larger A  pocket, and the 
sphingosine backbone is bound in the F  pocket. N20, N42, and N165 
represent the three ordered N-linked glycosylation sites that carry at least 
the remaining proximal N-acetylglucosamine residue after deglycosylation. 
(C) The chemical structure of the sulfatide used in this study and other 
CD1d ligands, such as PC (6), iGB3 (20), and the short-chain  -GalCer 
variant PBS-25 (11) for structural comparison. The length of the individual 
alkyl chains is given as the number of carbon atoms (C12–C26).JEM VOL. 202, December 5, 2005 1521
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bone, the  2-helix (Asp153, Thr156, and Gln154) is more
involved in stabilizing the galactosyl headgroup. Neverthe-
less, Arg79 hydrogen bonds to the 6  hydroxyl group of the
galactose, thereby fixing the orientation of galactose between
the  1- and  2-helices in concert with Asp153, which
interacts with the 2  hydroxyl group on the opposite side
of the galactose. The sulfate group is only loosely bound,
which explains its high B-values ( 70Å2) compared with
the rest of the ligand ( 40Å2) or the surrounding CD1 resi-
dues (24–53Å2).
Although the sulfated galactose headgroup makes an ad-
ditional hydrogen bond with CD1d, as compared with the
short-chain  -GalCer variant PBS-25 (11), its electron den-
sity is less well-defined. The  -linkage between the galactose
and the ceramide backbone in the sulfatide results in a much
higher degree of solvent exposure of the headgroup, whereas
the two short hydrogen bonds (2.5Å and 2.6Å) between
Asp153 and the  -linked galactose of PBS-25 pull the galac-
tose toward the  2-helix in an orientation horizontal to the
CD1 surface, which results in more intimate contacts with
CD1d, as reflected by similar B-values of the PBS-25 galac-
tose and the surrounding CD1 residues.
Comparison of  - versus  -anomeric ligands
A comparison of the orientation of the sulfatide and the PBS-
25 ligand in the mCD1d binding groove (Fig. 5, A and B) il-
lustrates that their lipid backbones are bound in a similar loca-
tion, likely due to the specific hydrogen bonding between
the ceramide moiety and the CD1 residues, whereas the dif-
ferent linkage between the galactose headgroups and the lipid
(  vs.  ) results in conformational differences between each
CD1d–lipid complex. The  -anomeric galactose (sulfatide) is
highly exposed and projects out of the binding groove per-
pendicular to the  1- and  2-helices (Fig. 5 A), whereas the
Figure 3. Conformation of the sulfatide in the CD1d-binding 
groove. After refinement, a 2Fo-Fc electron density map was calculated 
and contoured at 1  as a blue mesh around the ligand (yellow). Several 
important contact residues that are involved in ligand binding are 
depicted and labeled. (A) Side view, after removing the  2-helix for 
clarity. (B) View looking down into the CD1d-binding groove (TCR view). 
The sulfogalactosyl headgroup is omitted to highlight the well-defined 
electron density around the branching point of the lipid backbone, which 
we propose acts as a constraint to orient the different alkyl chains into 
their specific binding pockets.
Figure 4. Stereo view of the hydrogen–bond network between 
sulfatide and CD1d. The sulfatide ligand bound in the CD1d-binding 
groove is shown in a rear view from the COOH-terminal end of the  1-helix. 
Hydrogen bonds between the protein and the ligand residues are depicted 
as blue dashed lines and range in distance from 2.5Å to 3.5Å. The  1-helix 
residues Arg79 (R79), Asp80 (D80), and Met69 (M69) mainly bind the lipid 
backbone, whereas Asp153 (D153), Thr156 (T156), and Gln154 (Q154) of 
the  2-helix interact more closely with the galactose headgroup.STRUCTURE OF THE MOUSE CD1D–SULFATIDE COMPLEX | Zajonc et al. 1522
 -anomeric galactose (PBS-25) sits flat atop the binding
groove between both helices, thereby burying the lipid back-
bone while simultaneously exposing less surface area for rec-
ognition by the semi-invariant V 14 NKT cell receptor (Fig.
5 A and B, bottom). However, the short-chain  -GalCer
ligand PBS-25 induces the formation of a roof above the F 
pocket (Fig. 5 B) from CD1d residues, which can now play a
role in CD1d–TCR interaction. Small chemical differences
in the structure and binding of CD1d-specific ligands can
then be directly transmitted to the CD1d surface and, there-
fore, can aid in ligand discrimination by NKT cells. In the
case of the sulfatide ligand, where the galactosylsulfate moiety
sticks out of the groove, interaction with the variant sul-
fatide-reactive NKT cells is likely to be different from iNKT
cells. Here, the TCR has to accommodate a more protruding
headgroup and a different conformation of residues on the
CD1d surface. In addition, the sulfatide ligand exposes more
of its lipid backbone, which could now play a role in the T
cell–recognition process and help explain the biological dif-
ferences among various sulfatide species that have different
length fatty acid chains (Fig. 1 A).
Comparison of sulfatide binding by CD1d and CD1a
To compare the binding of sulfatides to different CD1 iso-
types, the mouse CD1d–sulfatide (Fig. 5 A) complex was
analyzed against the previously determined CD1a–sulfatide
structure (Fig. 5 C; reference 7). In both cases, the  -linked
galactose moieties face upward and are either sandwiched
between both  -helices (CD1a) or 90  rotated, sitting above
the binding groove (mCD1d). In each case, the sulfate is the
most exposed group of the ligand and the major antigenic
epitope, as sulfate-lacking  -GalCer is not antigenic (unpub-
lished data). Interestingly, the sulfate ligand is inserted into
the two CD1 binding grooves in opposite orientations. In
CD1a, the sphingosine backbone occupies the fixed-size A 
pocket (C18, molecular ruler), and the fatty acid tail end ex-
tends out of the F  pocket (C18) at the CD1 surface. In
mCD1d, the A  pocket is much larger and fully accommo-
dates the longer fatty acid chain (C24), whereas the sphingo-
sine backbone now occupies the smaller F  pocket. In either
case, the more restricted of the two CD1 binding pockets
binds the fixed-length sphingosine chain, whereas the larger
(CD1d) or more open-ended (CD1a) pockets bind the more
variable fatty acid. Thus, two different modes of sulfatide
binding are found in these CD1 isoforms. In CD1a, the
binding groove is fully occupied by the ligand, and any vari-
ation in the length of the fatty acid can be accommodated by
extension outside the binding groove, which can then di-
rectly translate into possible direct contact with the TCR. In
mCD1d, the shorter fatty acid chains result in partial filling
of the A  pocket. Depending on the extent of the A  pocket
that is not occupied by a ligand, a pocket-stabilizing factor,
as observed for the short-chain  -GalCer variant PBS-25, is
then recruited to fill up the unoccupied cavity to form a sta-
ble complex (11). In mouse CD1d, the corresponding T cell
would not directly see variations in fatty acid chain length at
the CD1 surface, whereas for CD1a, these subtle differences
in length can directly affect T cell stimulation (23).
DISCUSSION
The CD1 family of glycosylated cell-surface receptors con-
stantly surveys the lipid content of APCs by intracellular traf-
ficking through the various endosomal compartments. The
number and different classes of lipids that are now known to
act as ligands at the cell surface of APCs for specific T cells
have increased significantly in the last few years and include
phosphoglycerolipids, sphingolipids, diacylated glycerolipids,
lipopeptides, mycolates, phosphomycoketides, and small hy-
drophobic compounds (for review see references 13–15).
Some of these CD1 ligands promiscuously bind to all CD1
isotypes (e.g., sulfatide), whereas others are isoform-specific.
For example, mycolates are only bound to CD1b, whereas
Figure 5. Comparative binding analysis of different CD1d ligands. 
The CD1d binding pocket is shown as a transparent molecular surface in a 
side view (top) or top view (bottom), either with (A) bound cis-teracosenoyl 
sulfatide (C24:1) or with (B) the short-chain  -GalCer variant PBS-25 (PDB 
code 1Z5L). Although the galactose of sulfatide presented by CD1d is more 
exposed and sticks out from the center of the groove, that of PBS-25 sits 
more closely above the CD1d surface while burying the lipid backbone 
underneath. (C) The stearoyl sulfatide (C18:0) ligand is more nestled in the 
CD1a-binding groove (PDB code 1ONQ), whereas the fatty acid tail end is 
exposed at the CD1 surface.JEM VOL. 202, December 5, 2005 1523
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phosphomycoketides bind to CD1c. These observations were
at first surprising. Sulfatides and lipopeptides, which have
quite different chemical composition, can both bind to CD1a
but do so in a way that does not alter the structure of the
CD1a-binding groove. Both ligands maneuver into the bind-
ing groove and attain an optimal fit without inducing any
changes in the CD1 conformation (7, 8). In contrast, struc-
tures of mCD1d in complex with either PC, sulfatide, or the
short-chain   -GalCer PBS-25 show interesting structural
changes at the T cell–recognition surface of CD1. Compared
with the first crystal structure of mouse CD1d, to which an
endogenous PC ligand was bound (5, 6), binding of the
short-chain  -GalCer variant results in an alteration at the
CD1 surface, which leads to the formation of a roof above
the F  portal (11). This induced fit, however, has not been
observed in the structure of mCD1d–sulfatide. Although
both sulfatide and  -GalCer are glycosphingolipids, they dif-
fer in their chemical structure, not only in the linkage to their
galactosyl headgroups, but also in their ceramide lipid back-
bone.  -GalCer is based on phytoceramide, which has 3  and
4  OH groups, whereas the ceramide of sulfatide has a 4  OH
group and a 4 –5  unsaturation. This additional 4  OH group
of  -GalCer forms a second hydrogen bond with Asp80, and
the  -anomeric galactose forms tight hydrogen bonds with
Asp153 of the  2-helix. We propose that this tighter hydro-
gen bond interaction of  -GalCer with both  -helices results
in the structural changes observed in the mouse CD1d– -
GalCer complex. PC is a glycerolipid and its lipid backbone
diacylglycerol, as well as the phosphorylcholine headgroup,
interestingly form fewer hydrogen bonds with CD1 and,
therefore, do not appear to induce any structural changes, al-
though no truly “empty” structure is known. However, the
crystal structure of human CD1d with bound full-length
 -GalCer shows that under certain experimental conditions,
such as refolding without ligands, the protein can undergo
structural changes that partially close the binding groove.
Two CD1d molecules were observed in the crystal structure:
one was loaded with  -GalCer, whereas the other was
empty. However, whether this capacity of human CD1d to
close the binding groove in absence of any detectable ligand
is biologically significant remains elusive. Under physiological
conditions, such as during folding in the ER, lipids are al-
ways present to stabilize the hydrophobic CD1d binding
groove, thereby rendering any requirement for gross struc-
tural changes unnecessary.
All of the four lipid ligands that have been crystallized in
complex with either human (12) or mouse (6, 11) CD1d so
far show a common mode of lipid binding. The C18 sphin-
gosine chain is always inserted in the F  pocket, and fatty
acid (C8–C26) is always inserted in the A  pocket. This orien-
tation is similar for PC, where the shorter fatty acid chain
(C12) is inserted in the A  pocket and the longer fatty acid
(C24) in the F  pocket. Nevertheless, a sphingolipid with a
C18 fatty acid, as found in sulfatides from natural sources,
could insert its two alkyl chains in either pocket if the length
of the alkyl chain is the only factor responsible for ligand
binding. But the crystal structure of the CD1d– -GalCer
(PBS-25) complex revealed that the short fatty acid (C8) is
surprisingly inserted only in the A  pocket. The orientation
still needs to be determined for the recently identified family
of  -anomeric microbial ligands, the glycuronosyl ceramides
(C14; references 24 and 25). Thus, we propose that the
N-amide linkage between the fatty acid and the sphingosine
together with the hydroxyl groups of the sphingosine chain
(Fig. 2 C, highlighted in yellow), which forms a precise hy-
drogen-bonding network with CD1, constrains the cer-
amide backbone that orients the respective tails into the A 
and F  pockets.
It is not known whether the immunodominance of cis-
tetracosenoyl sulfatide is due to a more efficient binding to
CD1d or to the presence of specific TCR repertoires that
are stimulated preferentially by individual sulfatide species.
In this regard, it is interesting to note that the T cell hybrid-
oma specific for lyso-sulfatide does not recognize any of the
other sulfatides examined so far (unpublished data). Whether
NKT cells specific for each individual sulfatide express a
unique TCR or whether overlapping TCR repertoires exist
is currently not clear and should be determined by generat-
ing T cell hybridomas reactive to each of the individual sul-
fatides. Of interest, however, is that although the hydrogen
bonding network formed between the lipid backbone and
CD1d is responsible for the orientation of the different lipid
ligands in the binding groove, slight differences in the posi-
tioning of sulfatide and  -GalCer can be observed when
both structures are superimposed (not depicted). The same is
true when the binding of  -GalCer to CD1d is compared in
both mouse and human crystal structures. The exchange of
one residue at the CD1d surface (Trp153 in human and
Gly155 in mouse) results in a different positioning of the ga-
lactose, whereas the lipid backbone is bound in the same ori-
entation (26). Therefore, it is possible that the biological dif-
ferences between the different sulfatide species shown in Fig.
1 A are not only the result of differential loading characteris-
tics of the ligands, but rather the consequence of subtle
structural differences upon ligand binding due to either dif-
ferences in fatty acid chain length and/or saturation (C16 vs.
C24:1), or, in case of lyso-sulfatide, the complete lack of a
fatty acid chain. However, it cannot be completely ruled out
that the stronger NKT cell activation by cis-tetracosenoyl
sulfatide is a result of the increased solubility of the mono-
unsaturated and more polar nervonyl (C24:1) fatty acid versus
the fully saturated tetracosanoyl (C24:0) fatty acid, which
could lead to an increased efficiency of loading onto CD1.
Recognition of sulfatide by CD1d-restricted NKT cells
has important implications in autoimmune diseases of the
CNS, as sulfatides are one of the major glycolipid compo-
nents of the myelin membranes that are targeted in such dis-
eases as multiple sclerosis (MS). MS is a demyelinating dis-
ease mediated by a T cell–guided immune response that is
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or induced after the peripheral activation by a systemic mo-
lecular mimicry response (27, 28). Indeed, in MS patients,
increased serum levels of glycolipids (29, 30) and antibodies
directed against them have been reported (31–34). T cells
specific for glycolipids have been isolated from MS patients.
Their frequency in five active MS patients was three times
higher compared with five normal individuals (35). Re-
cently, it has been demonstrated that sulfatide binds promis-
cuously to all of the CD1a, CD1b, CD1c, and CD1d iso-
forms (36). Because CD1 molecules are up-regulated on
macrophages in areas of demyelination in chronic-active MS
lesions but not in silent lesions in the brain (37), it is possible
that self-glycolipids from myelin could be presented during
local inflammation to T cells. Microglia, as well as infiltrating
macrophages, could either engulf myelin components or in-
ternalize them by Fc receptors or by complement recep-
tor–mediated phagocytosis after binding to myelin-specific
antibodies. Thus, activated APCs in the CNS could not
only present peptides (MHC) to T cells, but also glycolipids
(CD1). Thus, myelin glycolipid–reactive T cells could po-
tentially influence the inflammation and demyelination in
the CNS. It is clear from our data (19 and unpublished data)
that the peripheral activation of sulfatide-reactive T cells af-
ter adjuvant-free administration of sulfatide ameliorates ex-
perimental autoimmune disease of the CNS. Because CD1
molecules, unlike the classical MHC molecules, are non-
polymorphic, insight into the molecular recognition of sul-
fatide by the CD1d molecules and their interaction with a
unique CD1d-restricted NKT cell population will be ex-
tremely valuable in the potential development of non-HLA–
dependent therapeutic approaches for autoimmune demyeli-
nating diseases in humans.
MATERIALS AND METHODS
Mice. 6–8-week-old female C57BL/6 or SJL/J (CD1d / ) mice were
purchased from The Jackson Laboratory. C57BL/6 (CD1d / ) mice were
originally generated in the laboratory of L. Van Kaer (Vanderbilt Univer-
sity, Nashville, TN) and were provided by M. Kronenberg (La Jolla Insti-
tute of Allergy and Immunology, La Jolla, CA). All animals were housed
under specific pathogen-free conditions, and animal protocols were ap-
proved by the Institutional Animal Care and Use Committee of the Torrey
Pines Institute for Molecular Studies.
Reagents. Purified sulfatides from bovine myelin and other semi-synthetic
sulfatides, including lyso-sulfatide, palmitoyl-sulfatide, and tetracosanoyl-
sulfatide, were purchased from Matreya Inc. Synthetic cis-tetracosenoyl sul-
fatide was synthesized as reported previously (38). For biological experi-
ments, lipids were dissolved in vehicle (0.5% Tween 20 and 0.9% NaCl
solution) and diluted in PBS. For structural studies, cis-teracosenoyl sul-
fatide was dissolved in DMSO. All monoclonal antibodies were purchased
from BD Biosciences.
Cell preparation. Hepatic lymphocytes were isolated using established
Percoll gradient methods. In brief, animals were killed by CO2 inhalation
and perfused with chilled PBS. To obtain lymphocytes, the liver was re-
moved, cut into small pieces, passed through a 70- m nylon cell strainer
(Falcon; Becton Dickinson), and suspended in DMEM supplemented with
2% heat-inactivated FBS. After centrifugation (1,500 g for 10 min), the cell
pellet was washed and resuspended in the same medium. Lymphocytes were
isolated from parenchymal hepatocytes, nuclei, and Kupffer cells by Percoll
(35% Percoll containing 100 U/ml heparin) gradient separation. Spleno-
cytes were obtained by passing the spleen through a 70- m nylon strainer
and suspension in DMEM with 2% heat-inactivated FBS. Erythrocytes
were lysed with RBC lysis buffer (BD Biosciences).
Monoclonal antibodies and flow cytometry. Mononuclear cells were
isolated and suspended in FACS buffer (1–2   106/ml) containing 0.02%
NaN3 in PBS (wt/vol) and 2% FBS (vol/vol) and treated with antibodies
against FcR-  (2.4G2) to block nonspecific binding and then labeled with
the indicated monoclonal antibodies. For flow cytometry staining, 2.5  g of
tetramerized mCD1d was used. Flow cytometric analysis was performed on
a FACSCalibur instrument using CELLQuest software (Becton Dickinson).
Tetrameric mCD1d–lipid complexes. Mouse CD1d protein was gen-
erated using the baculovirus expression system essentially as described previ-
ously (19). Unloaded mCD1d tetramers were prepared by preincubating
biotinylated mCD1d protein with vehicle only. To produce glycolipid–
mCD1d tetramers, biotinylated mCD1d protein was incubated with sul-
fatide at a molar ratio of 1:6 for 18–20 h at 22 C.
Measurement of proliferative and cytokine responses. For prolifera-
tive response to the self-glycolipids, 8   105 splenocytes from naive
C57BL/6 (CD1d / ) or CD1d /  mice were cultured in vitro for 72 h in
the presence of increasing concentrations of cis-tetracosenoyl sulfatide
(5–50  g/ml). [3H]thymidine incorporation was quantitated as described
previously (19, 39). For cytokine secretion, supernatants from 48-h cultures
were collected and IFN-  and IL-4 levels were determined using typical
sandwich ELISA assays using reagents from BD Biosciences as described
previously (19, 39). IL-2 secretion by sulfatide-reactive NKT cell hybrido-
mas was determined in culture supernatants by standard ELISA.
In vitro loading of sulfatides onto mouse CD1d. Soluble mouse
CD1d (9  g/18  l in PBS) was mixed with 4  g (2.0  l) of purified bo-
vine brain–derived sulfatide or the synthetic cis-tetracosenoyl sulfatide and
incubated at 37 C for 6 h followed by washing with 500  l of PBS and
concentrated using 10 kD mol wt cut-off centrifugal concentrators (Milli-
pore). After adjusting the remaining volume, equal amounts of protein were
subjected to IEF gel electrophoresis to monitor the loading efficiency of sul-
fatide onto CD1d.
Protein expression, purification, and crystallization. The baculovi-
rus transfer vector pAcUW51 (BD Biosciences) containing the nucleic acid
sequence for the extracellular domains of mCD1d and  2M, including sig-
nal sequence, was provided by M. Kronenberg. To engineer a CD1d con-
struct for crystallization purposes, the biotinylation domain, generally used
for the preparation of CD1 tetramers followed by a hexahistidine tag, was
removed by digestion with the restriction enzyme BamHI and replaced
with a short hexahistidine tag that was introduced by ligation of two com-
plementary BamHI-restricted oligonucleotides. A SalI site was incorporated
in the oligonucleotide to verify the integration of the fragment by restric-
tion digestion. Three colonies were analyzed by sequencing to find one
clone with the right orientation of the hexahistidine tag. The constructed
plasmid was cotransfected into SF9 cells with BaculoGold DNA using Cell-
fectin reagent (Invitrogen) according to the manufacturer’s specifications.
After several rounds of virus amplification, the protein was expressed for 3 d
in shaking flasks (145 rpm) at 28 C using SF9 cells (2   106 cells/ml) with a
multiplicity of infection of  3. The expression experiment was typically
performed on a 5–8-liter scale. SF9 cells were removed from the cell culture
media by centrifugation, and the media was further concentrated to 1 liter
and washed several times with PBS buffer. The protein was purified from
the concentrated media by ion metal affinity chromatography on a Ni-
NTA resin (QIAGEN) in 50 mM Tris/HCl buffer, pH 8.0, followed by
anion-exchange chromatography using MonoQ HR 10/10 (GE Health-
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mM NaCl. Two of the four total N-linked carbohydrates were removed af-
ter the proximal N-acetyl glucosamine residue by Endo H cleavage, as
judged by mass spectrometry analysis (unpublished data). In brief, 1 mg
CD1d protein was incubated with 50 mU Endo H in 100 mM sodium ace-
tate, pH 5.9, at 37 C for 2 h and purified by size-exclusion chromatography
(Superdex S200 10/300 GL; GE Healthcare). The synthetic sulfatide ligand
was then loaded onto the partially deglycosylated protein by incubating 3
mg CD1d with a 10-fold molar excess of synthetic sulfatide (0.12 ml of a 5
mg/ml solution in DMSO) in 100 mM sodium acetate buffer, pH 5.9, for
6 h at 37 C with intermittent agitation. The loaded CD1d protein was pu-
rified by ion-exchange chromatography on a MonoQ column using a shal-
low gradient of NaCl (0–150 mM over 25 column volumes). Loading of
sulfatide onto CD1d was observed by native IEF gels that monitored a shift
toward the cathode due to the additional negative charge from the sulfate
moiety. The CD1d fractions from the MonoQ run were pooled and con-
centrated to 7.5 mg/ml in 10 mM Hepes, pH 7.5, and 25 mM NaCl. The
best crystals were obtained at 22 C by mixing 1  l protein (7.5 mg/ml)
with 1  l precipitant solution (2 M ammonium sulfate, 0.1 M sodium ca-
codylate, pH 6.5, 0.2 M NaCl, and 10 mM manganese chloride) and grown
for 2 wk for data collection.
Structure determination. Crystals were flash-cooled at a temperature of
100 K in mother liquor containing 25% glycerol. Diffraction data from a
single crystal was collected at Beamline 8.2.2 of the Advanced Light
Source, Berkeley, CA, and then later from another crystal at Beamline 11.1
of the Stanford Synchrotron Radiation Laboratory and processed to 2.7 Å
and 1.9 Å, respectively, with the Denzo-Scalepack suite (40) in spacegroup
P2 (unit cell dimensions: a   58.86 Å, b   74.84 Å, c   101.56 Å, and
    102.1 ). Two CD1–lipid complexes occupy the asymmetric unit with
an estimated solvent content of 53.8% based on a Matthews’ coefficient
(Vm) of 2.66 A3/Da. Molecular replacement in P21 was performed with the
lower resolution dataset in CCP4 (41) using the program MOLREP (42)
and the CD1d-PBS-25 structure (15ZL) as the search model, with the
ligand removed, which resulted in a Rcryst of 48.2% and a correlation coef-
ficient of 0.46. Subsequent rigid-body refinement in REFMAC 5.2 to a
resolution of 3.5 Å resulted in an Rcryst of 41.4%. The initial refinement in-
cluded several rounds of restrained refinement against the maximum likeli-
hood target in REFMAC 5.2. Tight restraints were maintained between
the two molecules in the asymmetric unit throughout the refinement of
the lower resolution dataset. At a later stage of refinement, carbohydrates
were built at 5 out of the 8 N-linked glycosylation sites in both CD1 mol-
ecules. When the 1.9 Å high resolution dataset became available, it was
then used for subsequent refinement of the model derived from the 2.7 Å
resolution data. Before model building and restrained refinement, one
round of rigid-body refinement was performed to 3.5 Å resolution that re-
sulted in an Rcryst of 28%. Tight noncrystallographic symmetry restraints
were applied only during the first round of refinement and then not used
further, as they resulted in an increase in the Rfree value. The refinement
progress was judged by monitoring the Rfree for cross-validation (43). The
model was rebuilt into  A-weighted 2Fo–Fc and Fo–Fc difference electron
density maps using the program O (44). Water molecules were assigned
during refinement in REFMAC using the water ARP module for  3 
peaks in an Fo–Fc map and retained if they satisfied hydrogen-bonding cri-
teria and returned 2Fo–Fc density  1  after refinement. Starting coordi-
nates for the sulfatide ligand were obtained from the CD1a–sulfatide struc-
ture (1ONQ) and modified accordingly using the molecular modeling
system INSIGHT II (Accelrys, Inc.). The sulfatide library for REFMAC
(45) was created using the Dundee PRODRG2 server (46). Final refine-
ment steps were performed using the translation, libration, and screw-rota-
tion displacement procedure in REFMAC (47) with a total of six anisotro-
pic domains (three per complex:  1- 2 domain,  3-domain, and  2M)
and resulted in improved electron density maps for the glycolipid ligand
and a further drop in Rfree. The CD1d–sulfatide structure has a final Rcryst
of 18.6% and an Rfree of 24.8%. The quality of the model (Table I) was as-
sessed with the program Molprobity (48).
Structure presentation. The program Pymol (49) was used to prepare
Figs. 2, 3, and 4. The programs Molscript (50), GRASP (51), and Raster3D
(52) were used to prepare Fig. 5.
Accession codes. Coordinates and structure factors for the CD1d–sul-
fatide complex have been deposited in the Protein Data Bank under acces-
sion code 2AKR.
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